187 related articles for article (PubMed ID: 32986657)
21. Immune infiltration profiling in gastric cancer and their clinical implications.
Ren F; Zhao Q; Zhao M; Zhu S; Liu B; Bukhari I; Zhang K; Wu W; Fu Y; Yu Y; Tang Y; Zheng P; Mi Y
Cancer Sci; 2021 Sep; 112(9):3569-3584. PubMed ID: 34251747
[TBL] [Abstract][Full Text] [Related]
22. GHRL as a prognostic biomarker correlated with immune infiltrates and progression of precancerous lesions in gastric cancer.
Wang J; Liu D; Xie Y
Front Oncol; 2023; 13():1142017. PubMed ID: 37469414
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer.
Zhu L; Wang Z; Han W; Xu A
BMC Gastroenterol; 2023 Mar; 23(1):74. PubMed ID: 36918802
[TBL] [Abstract][Full Text] [Related]
24. The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma.
Zhang N; Wang D; Duan Y; Ayarick VA; Cao M; Wang Y; Zhang G; Wang Y
Pathol Res Pract; 2020 Jun; 216(6):152926. PubMed ID: 32327282
[TBL] [Abstract][Full Text] [Related]
25. Tumor Endothelial Marker TEM7 is a Prognostic Biomarker and Correlating with Immune Infiltrates in Gastric Cancer.
Geng L; Chen S; Gong Y; Zhou Y; Yang H; Tang L
Int J Gen Med; 2021; 14():10155-10171. PubMed ID: 34992436
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer.
Bao W; Zhu Z; Gao Y; Chen J
Pharm Res; 2022 May; 39(5):867-876. PubMed ID: 35578065
[TBL] [Abstract][Full Text] [Related]
27. Key Genes Associated with Prognosis and Tumor Infiltrating Immune Cells in Gastric Cancer Patients Identified by Cross-Database Analysis.
Zhang T; Wang BF; Wang XY; Xiang L; Zheng P; Li HY; Tao PX; Wang DF; Gu BH; Chen H
Cancer Biother Radiopharm; 2020 Nov; 35(9):696-710. PubMed ID: 32401038
[No Abstract] [Full Text] [Related]
28. Upregulation of ZHX2 predicts poor prognosis and is correlated with immune infiltration in gastric cancer.
Cheng A; Guo X; Dai X; Wang Z
FEBS Open Bio; 2021 Jun; 11(6):1785-1798. PubMed ID: 33837660
[TBL] [Abstract][Full Text] [Related]
29. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels.
Yang H; Li L; Liu X; Zhao Y
Med Sci Monit; 2021 Feb; 27():e927977. PubMed ID: 33539329
[TBL] [Abstract][Full Text] [Related]
30. Notch1/2/3/4 are prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Hu J; Yu J; Gan J; Song N; Shi L; Liu J; Zhang Z; Du J
Aging (Albany NY); 2020 Feb; 12(3):2595-2609. PubMed ID: 32028262
[TBL] [Abstract][Full Text] [Related]
31. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
[TBL] [Abstract][Full Text] [Related]
33. Infiltration of Gastric Cancer Stroma by Tumor-Infiltrating Lymphocytes Correlates with Mechanistic Target of Rapamycin Signaling.
Nakazawa N; Sohda M; Katayama A; Ide M; Shimoda Y; Tateno K; Watanabe T; Sano A; Sakai M; Yokobori T; Ogawa H; Oyama T; Shirabe K; Saeki H
Oncology; 2023; 101(8):520-526. PubMed ID: 37315539
[TBL] [Abstract][Full Text] [Related]
34. MTFR2, A Potential Biomarker for Prognosis and Immune Infiltrates, Promotes Progression of Gastric Cancer Based on Bioinformatics Analysis and Experiments.
Zhu H; Wang G; Zhu H; Xu A
J Cancer; 2021; 12(12):3611-3625. PubMed ID: 33995638
[No Abstract] [Full Text] [Related]
35. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.
Kim JY; Kim WG; Kwon CH; Park DY
Gastric Cancer; 2019 Nov; 22(6):1164-1175. PubMed ID: 31152268
[TBL] [Abstract][Full Text] [Related]
36. TMEM200A is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Fang F; Zhang T; Lei H; Shen X
PeerJ; 2023; 11():e15613. PubMed ID: 37404478
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis.
Liu X; Lin K; Huang X; Xie W; Xiang D; Ding N; Hu C; Shen X; Xue X; Huang Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):555-568. PubMed ID: 32025866
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer.
Pan S; Gao Q; Chen Q; Liu P; Tan Y; Liu F; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108258. PubMed ID: 34678693
[TBL] [Abstract][Full Text] [Related]
39. miR-588 is a prognostic marker in gastric cancer.
Chen Y; Zhang J; Gong W; Dai W; Xu X; Xu S
Aging (Albany NY); 2020 Dec; 13(2):2101-2117. PubMed ID: 33323542
[TBL] [Abstract][Full Text] [Related]
40. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
